MedPage Today May 24, 2024
— Phase III trial adds a fourth class shown to benefit this population
For people with type 2 diabetes and chronic kidney disease (CKD), semaglutide (Ozempic) reduced the risk of major kidney events and death from cardiovascular causes, the phase III FLOW trial showed.
Added to usual care, the GLP-1 receptor agonist reduced the primary composite endpoint — dialysis, kidney transplantation, an estimated glomerular filtration rate (eGFR) that falls at least 50% from baseline or to under 15 mL/min/1.73 m2, or death from kidney-related or cardiovascular causes — by 24% compared with placebo (HR 0.76, 95% CI 0.66-0.88).
The number needed to treat (NNT) for 3 years to prevent one such event was 20, reported Vlado Perkovic, MBBS, PhD, of...
Today's Sponsors
Today's Sponsor